Daiichi Sankyo

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Tests Quizartinib High Dose, Quizartinib Low Dose

For Acute Myeloid Leukemia and Leukemia

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Tests DS3790a, Combination drug, Combination drug

For Hematological Malignancies and B-cell Non-Hodgkin Lymphoma

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Tests DS9051b

For Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Tests Decitabine, Quizartinib, Venetoclax

For Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Tests DS-5141b

For Duchenne Muscular Dystrophy

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

Tests Pexidartinib

For Tenosynovial Giant Cell Tumor

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Tests DS-8201a, T-DM1

For HER2-Positive Primary Breast Cancer and Residual Invasive Breast Cancer

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Tests Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide

For Acute Myeloid Leukemia

Daiichi Sankyo is a Japanese pharmaceutical company with roots dating back to 1899 (formed through the 2005 merger of Daiichi Pharmaceutical and Sankyo). It is best known for cancer drugs called antibody-drug conjugates. Its FDA-approved rare disease medicines include Vanflyta (quizartinib), approved in July 2023 for newly diagnosed FLT3-ITD acute myeloid leukemia, and Turalio (pexidartinib), approved in August 2019 for adults with tenosynovial giant cell tumor that causes severe symptoms and cannot be helped by surgery. It is also running a first-in-human trial of DS9051b, a drug taken by mouth, in adrenocortical carcinoma (NCT07189403).

Daiichi Sankyo has active programs across 7 rare diseases: Acute Myeloid Leukemia, Adrenocortical Carcinoma, Cholangiocarcinoma, Duchenne Muscular Dystrophy, Fibrodysplasia Ossificans Progressiva, Myelodysplastic Syndromes, Tenosynovial Giant Cell Tumor. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.

Daiichi Sankyo is a diversified pharmaceutical company headquartered in Tokyo, Japan, founded in 2005. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 7 active rare disease programs including Acute Myeloid Leukemia, Adrenocortical Carcinoma, Cholangiocarcinoma. Many of its rare disease treatments hold orphan drug designations from the FDA.

The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Daiichi Sankyo, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.

To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.

Daiichi Sankyo was founded in 2005 and is headquartered in Tokyo, Japan. The company has been active for 21 years. It trades publicly under the ticker symbol 4568.